Apolipoprotein E ε4 and Age at Onset of Sporadic and Familial Alzheimer Disease in Caribbean Hispanics
Abstract
BACKGROUND: The primary effect of the apolipoprotein E epsilon4 (APOE epsilon4) allele is on the age at onset of Alzheimer disease (AD). OBJECTIVE: To investigate whether the presence of the APOE epsilon4 allele can account for the earlier age at onset of familial AD (FAD) compared with sporadic AD (SAD). DESIGN: Population-based, case series ascertained in a prospective study of aging and dementia in Medicare recipients aged 65 years or older. SETTING: Clinics in northern Manhattan and in the Dominican Republic and Puerto Rico. PARTICIPANTS: There were 680 Caribbean Hispanic subjects: 111 patients with FAD, with at least 1 family member with dementia; 163 patients with SAD; and 406 elderly persons without dementia or other illnesses. Main Outcome Measure Age at onset of dementia was examined in relation to frequency of APOE epsilon4. Sex, education, and medical risk factors for stroke, hypertension, diabetes, and heart disease were examined as effect modifiers. RESULTS: The mean age at onset of AD was significantly lower in FAD than in SAD, and a statistically significant dose effect of the APOE epsilon4 allele was present for age at onset in FAD (P = .001) but not in SAD. The age at onset in patients homozygous for the APOE epsilon4 allele with FAD and SAD was similar. Compared with SAD, the major difference was younger age at onset in patients with FAD who were heterozygous for the APOE epsilon4 allele and those without an APOE epsilon4 allele. CONCLUSIONS: Apolipoprotein E epsilon4 had a consistent lowering effect on age at onset of FAD, but this was attenuated in SAD. This suggests that among individuals with a family history of AD and the APOE epsilon4 allele, additional genetic or environmental factors may accelerate the onset of dementia.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
APOEε4 modifies the age at onset in both EOAD and LOAD.
“APOEε4 has been shown to modify the age at onset in both EOAD and LOAD [64–66].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [65]
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. L., & Stadlan, E. (2011) · Neurology · doi:10.1212/01.wnl.0000400650.92875.cf · Cited by 9,882 · see citing works
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · see citing works
A New Clinical Scale for the Staging of Dementia
Hughes, C. P., Berg, L., Danziger, W., Coben, L. A., & Martin, R. L. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.140.6.566 · Cited by 7,056 · see citing works
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921 · see citing works
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933 · see citing works
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · see citing works
The 1986 census of population and housing
Cornish, J. K. (1985) · Journal of the Australian Population Association · doi:10.1007/bf03041202 · Cited by 1,417 · see citing works
Tang, M.-X. (1998) · JAMA · doi:10.1001/jama.279.10.751 · Cited by 771 · see citing works
Self-citationIncidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan
Tang, M. ‐., Cross, P. S., Andrews, H., Jacobs, D. M., Small, S. A., Bell, K., Merchant, C., Lantigua, R., Costa, R., Stern, Y., et al. (2001) · Neurology · doi:10.1212/wnl.56.1.49 · Cited by 721 · see citing works
Self-citationApolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein
Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., Verkkoniemi, A., Niinistö, L., Halonen, P., & Kontula, K. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331902 · Cited by 493 · see citing works
The apolipoprotein ε4 allele in patients with Alzheimer's disease
Mayeux, R. P., Stern, Y., Ottman, R., Tatemichi, T. K., Tang, M., Maestre, G. E., Ngai, C. I., Tycko, B., & Ginsberg, H. N. (1993) · Annals of Neurology · doi:10.1002/ana.410340527 · Cited by 414 · see citing works
Self-citationSlooter, A. J. C., Cruts, M., Kalmijn, S., Hofman, A., Breteler, M. M. B., Van Broeckhoven, C., & van Duijn, C. M. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.964 · Cited by 399 · see citing works
Diagnosis of Dementia in a Heterogeneous Population
Stern, Y. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530290035009 · Cited by 370 · see citing works
A full genome scan for late onset Alzheimer's disease
Kehoe, P. G. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.2.237 · Cited by 356 · see citing works
Apolipoprotein E and alzheimer's disease: Ethnic variation in genotypic risks
Maestre, G. E., Ottman, R., Stern, Y., Gurland, B. J., Chun, M. R., Tang, M., Shelanski, M. L., Tycko, B., & Mayeux, R. P. (1995) · Annals of Neurology · doi:10.1002/ana.410370217 · Cited by 244 · see citing works
Self-citationTang, M. X., Maestre, G. E., Tsai, W., Liu, X., Feng, L., Chung, W.-Y., Chun, M. R., Schofield, P. R., Stern, Y., Tycko, B., et al. (1996) · PubMed Central · doi:10.7916/d80v9r96 · Cited by 184 · see citing works
Self-citationLack of an association between apolipoprotein E ϵ4 and Alzheimer's disease in elderly nigerians
Osuntokun, B. O., Sahota, A. S., Ogunniyi, A. O., Gureje, O., Baiyewu, O., Adeyinka, A. O., Oluwole, S., Komolafe, O. O., Hall, K. S., Unverzagt, F. W., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380319 · Cited by 158 · see citing works
Apolipoprotein E genotypes and Alzheimer's disease in a community study of elderly African Americans
Hendrie, H. C., Hall, K. S., Hui, S. L., Unverzagt, F. W., Yu, C., Lahiri, D. K., Sahota, A. S., Farlow, M. R., Musick, B. S., Brashear, A., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410370123 · Cited by 141 · see citing works
Duara, R., Barker, W., Lopez-Alberola, R., Loewenstein, D., Grau, L. B., Gilchrist, D. M., Sevush, S., & George‐Hyslop, P. S. (1996) · Neurology · doi:10.1212/wnl.46.6.1575 · Cited by 132 · see citing works
Lahiri, D. K., Sambamurti, K., & Bennett, D. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.024 · Cited by 130 · see citing works
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124 · see citing works
A comparison of familial and sporadic Alzheimer's disease
Duara, R., Lopez-Alberola, R. F., Barker, W. W., Loewenstein, D. A., Zatinsky, M., Eisdorfer, C. E., & Weinberg, G. B. (1993) · Neurology · doi:10.1212/wnl.43.7.1377 · Cited by 122 · see citing works
Focus on Alzheimer's Disease and Related Disorders
Papassotiropoulos, A., Wollmer, M. A., Tsolaki, M., Brunner, F., Molyva, D., Lütjohann, D., Nitsch, R. M., & Höck, C. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0720 · Cited by 104 · see citing works
Apolipoprotein E4 promotes the early deposition of Aβ42 and then Aβ40 in the elderly
Walker, L. C., Pahnke, J., Madauss, M., Vogelgesang, S., Pahnke, A., Herbst, E. W., Stausske, D., Walther, R., Kessler, C., & Warzok, R. (2000) · Acta Neuropathologica · doi:10.1007/s004010051190 · Cited by 81 · see citing works
Molecular pathogenesis of sporadic and familial forms of Alzheimer's disease
Ray, W. J., Ashall, F., & Goate, A. (1998) · Molecular Medicine Today · doi:10.1016/s1357-4310(98)01229-5 · Cited by 55 · see citing works
Heritability of plasma amyloid β in typical late‐onset Alzheimer’s disease pedigrees
Ertekin‐Taner, N., Graff‐Radford, N. R., Younkin, L. H., Eckman, C. B., Adamson, J. L., Schaid, D. J., Blangero, J., Hutton, M. L., & Younkin, S. G. (2001) · Genetic Epidemiology · doi:10.1002/gepi.1015 · Cited by 53 · see citing works
Lack of association between UBQLN1 and Alzheimer disease
Slifer, M. A., Martin, E. R., Bronson, P. G., Browning, C., Doraiswamy, P. M., Welsh-Bohmer, K. A., Gilbert, J. R., Haines, J. L., & Pericak‐Vance, M. A. (2006) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30298 · Cited by 30 · see citing works
Molecular Epidemiology of Alzheimer's Disease
Hyman, B. T., & Tanzi, R. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331910 · Cited by 23 · see citing works
Influence of APOE genotype on familial aggregation of AD in an urban population
Devi, G., Ottman, R., Tang, M. ‐., Marder, K. S., Stern, Y., Tycko, B., & Mayeux, R. P. (1999) · Neurology · doi:10.1212/wnl.53.4.789 · Cited by 22 · see citing works
Self-citationApolipoprotein(a) null phenotype is related to a delayed age at onset of Alzheimer's disease
Emanuele, E., Peros, E., Tomaino, C., et al. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.12.043 · Cited by 17 · see citing works
Corder, E. H., Basun, H., Lannfelt, L., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91588-5 · Cited by 14 · see citing works
A full genome scan for late onset Alzheimers disease
Owen, M. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82419-7 · Cited by 9 · see citing works
APOE Genotype, Family History of Dementia, and Alzheimer Disease Risk
Huang, W., Qiu, C., Strauss, E. I. V., Winblad, B. G., & Fratiglioni, L. (2004) · Archives of Neurology · doi:10.1001/archneur.61.12.1930 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Goldman, J. S., Hahn, S. E., Catania, J. W., Larusse-Eckert, S., Butson, M. B., Rumbaugh, M., Strecker, M. N., Roberts, J. S., Burke, W., Mayeux, R., et al. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e31821d69b8 · Cited by 393 · see citing works
Self-citationFernandez, C. G., Hamby, M. E., McReynolds, M. L., & Ray, W. J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00014 · Cited by 277 · see citing works
Sando, S. B., Melquist, S., Cannon, A., Hutton, M. L., Sletvold, O., Saltvedt, I., White, L. R., Lydersen, S., & Aasly, J. O. (2008) · BMC Neurology · doi:10.1186/1471-2377-8-9 · Cited by 261 · see citing works
APOE ε4 allele predicts faster cognitive decline in mild Alzheimer disease
Cosentino, S., Scarmeas, N., Helzner, E., Glymour, M. M., Brandt, J., Albert, M., Blacker, D., & Stern, Y. (2008) · Neurology · doi:10.1212/01.wnl.0000304038.37421.cc · Cited by 214 · see citing works
Genetic architecture of Alzheimer's disease
Neuner, S. M., TCW, J., & Goate, A. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104976 · Cited by 126 · see citing works
“Additionally, APOEε4 has been shown to modify the age at onset in both EOAD and LOAD (Houlden et al., 1994; Olarte et al., 2006; Locke et al., 1995).”
BackgroundLangbaum, J. B. S., Chen, K., Caselli, R. J., Lee, W., Reschke, C., Bandy, D., Alexander, G. E., Burns, C. M., Kaszniak, A. W., Reeder, S. A., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.30 · Cited by 100 · see citing works
APOE2 mitigates disease-related phenotypes in an isogenic hiPSC-based model of Alzheimer’s disease
Brookhouser, N., Raman, S., Frisch, C., Srinivasan, G., & Brafman, D. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01076-3 · Cited by 33 · see citing works
- Authors
- Olarte, L., Schupf, N., Lee, J. H., Tang, M.-X., Santana, V., Williamson, J., Maramreddy, P., Tycko, B., & Mayeux, R.
- Affiliations
- Columbia University Irving Medical Center (US)
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2006-11-01
- Volume
- 63
- Issue
- 11
- Pages
- 1586
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W1965486715
- Cited by
- 42
- References
- 35
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 3 · 2021: 3 · 2020: 6 · 2019: 2 · 2017: 1 · 2016: 3 · 2014: 2 · 2013: 2 · 2012: 2
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (AG07232, AG08702)
- National Institute on Aging (P01AG007232, AG 07232, P50AG008702)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- APOE ε4, Alzheimer's disease, age of onset, familial Alzheimer's disease, sporadic Alzheimer's disease, Caribbean Hispanics, dosage effect, genetic risk factors, family history of dementia, effect modifiers, older adults
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Gene Frequency, Genotype, Hispanic or Latino, Humans, Male, Prospective Studies, Risk Factors, Chi-Square Distribution, Age of Onset, Caribbean Region, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
